Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

scistats 225 posts  |  Last Activity: 15 hours ago Member since: Apr 5, 2009
  • scistats by scistats Apr 14, 2016 4:56 PM Flag

    Merrimack's new friend.
    Awwwww, so sweet!

    Sentiment: Strong Buy

  • Reply to

    Dilution Time- Conversion

    by spec_59 Apr 14, 2016 9:21 AM
    scistats scistats Apr 14, 2016 10:20 AM Flag

    These are Hercules Technology Growth Capital, Inc. notes?

  • Reply to

    Athersys Team in Japan - Met with PMDA

    by wall_street_titan Apr 14, 2016 6:55 AM
    scistats scistats Apr 14, 2016 9:33 AM Flag

    Something is going to happen here with ATHX.
    Lots of irons in the fire from UK to Japan.
    I still want to see Multistem for TB ASAP. The leaders in the field have already pointed Athersys in this direction with their publications.

    Sentiment: Strong Buy

  • scistats scistats Apr 14, 2016 9:27 AM Flag

    Nice to hear the team is staying on top of things.
    Multistem for antibiotic resistant Neisseria gonorrhoeae.

    Sentiment: Strong Buy

  • Reply to

    Athersys Team in Japan - Met with PMDA

    by wall_street_titan Apr 14, 2016 6:55 AM
    scistats scistats Apr 14, 2016 8:48 AM Flag

    This alone would be enough for big pharma to buy Athersys for 20 PPS if they want it cheap. Once ARDS is confirmed with any evidence....

    Sentiment: Strong Buy

  • Reply to

    Athersys Team in Japan - Met with PMDA

    by wall_street_titan Apr 14, 2016 6:55 AM
    scistats scistats Apr 14, 2016 8:43 AM Flag

    What about news out of the UK for the Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome?
    This study is currently recruiting participants, and the outcome should be immediately obvious.
    Per Mayo Clinic, "usually develops within a few hours to a few days after the original disease or trauma. Many people who develop ARDS don't survive."
    Breaking news should be coming from Geoff Bellingan, MD University College London Hospital.

    Sentiment: Strong Buy

  • Reply to

    Pre market

    by stocktock11 Apr 14, 2016 8:16 AM
    scistats scistats Apr 14, 2016 8:38 AM Flag

    Sold what? They are all buys?

    06:48 $ 2.37 Low 1,000
    06:48 $ 2.37 Low 1,000
    06:48 $ 2.37 Low 2,500
    06:48 $ 2.37 Low 4,200
    06:48 $ 2.37 Low 700
    06:47 $ 2.61 High 9,400

    Sentiment: Strong Buy

  • scistats scistats Apr 13, 2016 11:30 PM Flag

    Purpose
    This is a single arm pilot study of 64Cu-MM-302 and unlabeled MM-302 in combination with trastuzumab in 10 patients with advanced HER2+ cancer with new or progressive brain metastases. Patients will receive standard imaging at baseline, including FDG-PET/CT plus MR brain imaging. Patients will subsequently start protocol therapy with MM-302 and trastuzumab given on day 1 of an every 21-day dosing cycle, at the recommended phase 2 dose of 30 mg/m2. Patients will receive 64Cu-labeled MM-302 (3-5 mg/m2 doxorubicin) three hours after unlabeled dose of MM-302. Integrated MR/PET imaging of the brain and whole body will be performed at two time points following 64Cu-labeled MM-302 administration: (1) within 3 hours (+/- 1 hour) of labeled drug injection, and (2) 24 hours (+/- 6 hours) post-injection. Patients will continue to receive subsequent doses of unlabeled MM-302 plus trastuzumab every 3 weeks until clinical or radiographic disease progression (either in the brain or systemically) or unacceptable toxicity, whichever occurs soonest. MR brain imaging and FDG-PET/CT scans will be performed every 9 weeks to monitor for treatment response and disease progression.

    Sentiment: Strong Buy

  • Reply to

    poison pill

    by markifeldman Apr 13, 2016 4:36 PM
    scistats scistats Apr 13, 2016 6:56 PM Flag

    Holders
    As of
    March 1, 2016, there were approximately 530 holders of record of our common stock. Additionally, shares of common stock are held by financial institutions
    as nominees for beneficial owners that are deposited into participant accounts at the
    Depository Trust Company, which are considered to be held of record by
    Cede & Co. and are included in the holders of record as one stockhold

  • Reply to

    poison pill

    by markifeldman Apr 13, 2016 4:36 PM
    scistats scistats Apr 13, 2016 5:05 PM Flag

    "The company, Athersys Inc. of Cleveland, licensed the rights from the University of Minnesota, where the stem cell was discovered by Dr. Catherine M. Verfaillie and colleagues, university and company officials said."

    Sentiment: Strong Buy

  • Reply to

    poison pill

    by markifeldman Apr 13, 2016 4:36 PM
    scistats scistats Apr 13, 2016 4:51 PM Flag

    Indeed, the great mystery of the lack of insider shares held at ye ol'Athersys.

    What about the subsidiaries? How do they affect:
    1. A hostile takeover/buyout attempt
    2. Your estimation of who in management actually owns how much of Athersys

    BJ said he was concerned about a buyout, but are you being told the whole story?
    Do you see stock options coming to management soon?
    Going private is an option, or merging with Pfizer like Icagen?

    SUBSIDIARIES OF ATHERSYS, INC.
    ABT Holding Company (formerly Athersys, Inc.) Delaware
    Advanced Biotherapeutics, Inc. Delaware
    Athersys Limited United Kingdom
    ReGenesys LLC Delaware
    ReGenesys BVBA Belgium
    ReGenesys EU NV Belgium

    Sentiment: Strong Buy

  • scistats scistats Apr 12, 2016 9:43 AM Flag

    Why? This it was an intentional a full court press.
    Pete called in a play to blitz the competition, and the sales force executed.
    Yes, it was expensive, but Pete has now established brand MiMedx.
    They seem pretty confident.

  • So, MiMedx failed to assign unit sales to a single sales team member and had to pay double or triple sales commissions? They sent multiple salespeople to the same hospital, did not track who sold what or forgot to define territory??

    Sounds a bit rookie-esque?

    Or, perhaps they oversaturated to claim territory and accepted redundant costs. Think of it as a salesperson bonus to ensure market penetration at the cost of a few quarters now written off as establishment costs.

    Not their first rodeo for sure. Pete said this strategy will pay off. We shall see.

  • scistats scistats Apr 11, 2016 10:01 PM Flag

    House M D S2 [Episode 4] TB or Not TB - YouTube

    Sentiment: Strong Buy

  • scistats scistats Apr 11, 2016 10:00 PM Flag

    One-third of the world's population is thought to be infected with TB.
    watch?v=TYCtP_yKPqg

    Sentiment: Strong Buy

  • scistats scistats Apr 11, 2016 6:53 PM Flag

    These p-values are from the stroke phase 2 which lend credence to the ongoing Multistem ARDS trial in the UK and hopefully a future Multistem for active pulmonary TB trial per the thought leaders in the field suggesting MSCs will help.

    Sentiment: Strong Buy

  • scistats scistats Apr 11, 2016 4:57 PM Flag

    1,460,000 per year die from TB.

    Sentiment: Strong Buy

  • scistats scistats Apr 11, 2016 4:52 PM Flag

    "However, MultiStem treatment was associated with lower rates of mortality and life threatening adverse events (AEs), infections and pulmonary events."

    "The MultiStem treatment group had a lower rate of life threatening adverse events and death (p=0.04), and also exhibited lower rates of pulmonary events (p=0.08) and infections."

    ..."With respect to ARDS, we are encouraged by the apparent impact in this study on mortality, life threatening adverse events, INFECTION and pulmonary events, which together with our non-clinical study results in pulmonary injury models, suggests the potential for benefit in this patient population. We have a good balance sheet to support this ongoing work and remain confident that our MultiStem therapy and other technologies will have an important impact," concluded Dr. Van Bokkelen.

    Sentiment: Strong Buy

  • MULTISTEM: OFF-THE-SHELF for TB?

    "TB bacteria can trigger an inflammatory response in immune cells and surrounding lung tissue that can cause immune dysfunction and tissue damage. Bone marrow MSCs are known to migrate to areas of lung injury and inflammation and repair damaged tissue. They also modify the host immune response and could boost the clearance of TB bacteria."

    Co-author Professor Alimuddin Zumla, Professor of Infectious Diseases and International Health at UCL and a BRC-supported researcher, said: “The results of this novel and exciting study show that the current challenges and difficulties of treating multi-drug resistant TB are not insurmountable, and they bring a unique opportunity with a fresh solution to treat hundreds of thousands of people who die unnecessarily of drug-resistant TB.

    "Further evaluation in phase 2 trials is now urgently required to ascertain efficacy and further safety in different geographical regions such as South Africa where multi-drug resistant and extensively-drug resistant TB are rife.”

    Professor Markus Maeurer from Karolinska University Hospital in Stockholm, who led the research, explained a follow up with more patients is needed to establish the safety and efficacy of MSC therapy:

    “The procedures for obtaining stromal cells from the patient’s own bone marrow are relatively simple, and if successful in phase 2 trials, will provide a viable adjunctive therapy for patients with multi-drug resistant TB not responding to conventional drug treatment or those with severe lung damage.”

    MULTISTEM: OFF-THE-SHELF for TB?

    References:
    1. Archivum Immunologiae et Therapiae Experimentalis
    December 2015, Volume 63, Issue 6, pp 427-433
    2. First online: 23 June 2015
    Mesenchymal Stromal Cell Therapy in MDR/XDR Tuberculosis: A Concise Review
    3. The Lancet Respiratory Medicine
    Volume 2, No. 2, p108–122, February 2014
    4. University College London

    Sentiment: Strong Buy

  • scistats scistats Apr 11, 2016 4:33 PM Flag

    Bump.

    Sentiment: Strong Buy

SNY
39.07+0.32(+0.83%)May 5 4:01 PMEDT